Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Eng. sanit. ambient ; 25(4): 635-648, jul.-ago. 2020. tab, graf
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1133802

RESUMEN

RESUMO O presente estudo analisou o potencial de recuperação energética dos resíduos sólidos urbanos (RSU) e o balanço de emissões de gases de efeito estufa (GEE) resultante no município do Rio de Janeiro, Rio de Janeiro, com base em três cenários tecnológicos alternativos. Os potenciais de geração foram calculados para a recuperação de gás de lixo (GDL) em 363,98 GWhe.ano-1 e 0,181 MWhe.t-1, para a biodigestão anaeróbica em 367,27 GWhe.ano-1 e 0,247 MWhe.t-1; e para a incineração em 1.139,33 GWhe.ano-1 e 0,459 MWhe.t-1. Os indicadores de intensidade de carbono mostram que, ao se considerar somente as emissões de GEE de combustão, a recuperação de GDL e a biodigestão anaeróbica apresentam os menores valores (7,488.10-4 tCO2eq.MWhe-1), enquanto a incineração apresenta o valor de 1,248 tCO2eq.MWhe-1. Por outro lado, ao se considerar também as emissões de aterro associadas, os indicadores dos dois primeiros cenários correspondem a 8,191 e 3,552 tCO2eq.MWhe-1, respectivamente.


ABSTRACT The present study analyzes the energy recovery potential of municipal solid waste (MSW) and the resulting greenhouse gas (GHG) emission balance in the city of Rio de Janeiro, Rio de Janeiro, Brazil, based on three alternative technological scenarios. The generation potentials were calculated for waste gas recovery (WGR) to be 363.98 GWhe.year-1 and 0.181 MWhe.t-1, 367.27 GWhe.year-1 and 0.247 MWhe.t-1 for anaerobic biodigestion, and 1.139.33 GWhe.year-1 and 0.459 MWhe.t-1 for incineration. Carbon intensity indicators show that, when only considering GHG emissions from the combustion process, WGR recovery and anaerobic biodigestion present the lowest values, of 7.488.10-4 tCO2eq.MWhe-1, while the value for incineration corresponds to 1.248 tCO2eq.MWhe-1. On the other hand, when considering associated landfill GHG emissions, the indicators in the first two scenarios correspond to 8.191 and 3.552 tCO2eq.MWhe-1, respectively.

2.
Int. braz. j. urol ; 45(2): 315-324, Mar.-Apr. 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1002193

RESUMEN

ABSTRACT Objectives: To evaluate the neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor for response of high risk non muscle invasive bladder cancer (HRNMIBC) treated with BCG therapy. Materials and Methods: Between March 2010 and February 2014 in a tertiary center 100 consecutive patients with newly diagnosed HRNMIBC were retrospectively analyzed. Patients were divided according to NLR value: 46 patients with NLR value less than 3 (NLR < 3 group), and 54 patients with NLR value more than 3 (NLR ≥ 3 group). At the end of follow-up 52 patients were high grade disease free (BCG-responder group) and 48 patients underwent radical cystectomy for high grade recurrence or progression to muscle invasive disease (BCG non-responder group). The average follow-up was 60 months. Intervention: analysis and correlation of preoperative NLR value with response to BCG in terms of recurrence and progression. Results: The optimal cut-off for NLR was ≥ 3 according to the receiver operating characteristics analysis (AUC 0.760, 95% CI, 0.669-0.850). Mean NLR value was 3.65 ± 1.16 in BCG non-responder group and 2.61 ± 0.77 in BCG responder group (p = 0.01). NLR correlated with recurrence (r = 0.55, p = 0.01) and progression risk scores (r = 0.49, p = 0.01). In multivariate analysis, NLR (p = 0.02) and EORTC recurrence risk groups (p = 0.01) were associated to the primary endpoint. The log-rank test showed statistically significant difference between NLR < 3 and NLR ≥ 3 curves (p < 0.05). Conclusions: NLR value preoperatively evaluated could be a useful tool to predict BCG response of HRNMIBC. These results could lead to the development of prospective studies to assess the real prognostic value of NLR in HRNMIBC.


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Vacuna BCG/uso terapéutico , Linfocitos/patología , Carcinoma de Células Transicionales/tratamiento farmacológico , Adyuvantes Inmunológicos/uso terapéutico , Neutrófilos/patología , Pronóstico , Neoplasias de la Vejiga Urinaria/cirugía , Neoplasias de la Vejiga Urinaria/patología , Carcinoma de Células Transicionales/cirugía , Carcinoma de Células Transicionales/patología , Biomarcadores de Tumor/sangre , Cistectomía , Estudios Retrospectivos , Recuento de Linfocitos , Progresión de la Enfermedad , Clasificación del Tumor , Persona de Mediana Edad , Recurrencia Local de Neoplasia/cirugía , Estadificación de Neoplasias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA